Creatine Monohydrate: Mechanism, Evidence, and How I Formulated It

Creatine monohydrate is a naturally occurring compound synthesised in the liver and kidneys, and also obtained from red meat and fish. At the cellular level, it buffers adenosine triphosphate (ATP) regeneration during high-intensity muscle contraction. I include 5000 mg of micronised powder in KōJō Daily Formula because the evidence is substantial: Antonio et al. (2021) analysed over 300 studies and found creatine monohydrate increases muscle strength and power output in trained individuals, with effect sizes ranging from small to moderate depending on training age and protocol. This deep-dive covers the molecular mechanism, clinical evidence, dosing rationale, and why I chose micronised powder over alternative forms.

Mechanism of Action

Creatine monohydrate enters muscle cells via the creatine transporter type 1 (SLC6A8), a sodium-dependent amino acid transporter embedded in the sarcolemma. Once intracellular, creatine is phosphorylated by creatine kinase (CK) to form phosphocreatine (PCr), a high-energy phosphate compound stored in the sarcoplasm. During muscle contraction, the phosphate group from PCr is rapidly transferred to adenosine diphosphate (ADP) by the creatine kinase reaction, regenerating ATP. This is the primary energy currency of muscle contraction, and replenishing ATP availability is especially critical during repeated bouts of maximal or near-maximal effort lasting 6–30 seconds.

The mechanism is quantifiable: muscle phosphocreatine stores increase by approximately 15–20% with chronic supplementation, which correlates with improvements in power output during repeated sprints or heavy resistance training. This is not a stimulant effect—creatine does not increase adrenaline or heart rate—but rather a substrate-level energetic enhancement. The effect is most pronounced in tissues with high ATP turnover and limited oxidative capacity, which is why skeletal muscle responds more robustly than other tissues.

I chose micronised powder because particle size matters for absorption kinetics. Micronisation reduces particle diameter to 5–10 microns, increasing surface area and dissolution rate in aqueous solution. This does not change the fundamental mechanism—phosphocreatine synthesis is identical regardless of powder form—but it may improve absorption consistency and reduce gastrointestinal transit time, which I address in the Bioavailability section below.

Clinical Evidence

The evidence base for creatine monohydrate is among the strongest for any sports supplement. Antonio et al. (2021) conducted a thorough scoping review of over 300 peer-reviewed studies and found consistent evidence that creatine monohydrate increases maximal strength and power output in resistance-trained populations. The median effect size was small to moderate (Cohen's d = 0.3–0.6), with heterogeneity driven by training experience, age, and baseline muscle mass. Untrained individuals and older adults showed larger relative improvements, whilst elite athletes showed smaller but still meaningful enhancements.

For endurance performance, the picture is more mixed. Fernández-Landa et al. (2023) performed a systematic review and meta-analysis of creatine monohydrate in trained endurance athletes and found heterogeneous effects. In aerobic endurance activities lasting >3 minutes, the effect was negligible (d < 0.1). However, in repeated-sprint protocols within endurance sports—such as cycling sprint intervals or football repeated sprints—creatine showed small positive effects (d = 0.2–0.4). The mechanism is straightforward: endurance activities rely primarily on oxidative phosphorylation, not phosphocreatine buffering, so creatine offers little advantage. Repeated sprinting within an endurance context recruits anaerobic pathways and benefits from PCr availability.

Beyond athletic performance, emerging evidence suggests cognitive and neuroprotective roles. Xu et al. (2026) conducted a systematic review and meta-analysis of creatine supplementation on cognitive function in adults and found a small positive effect on memory and processing speed (pooled d = 0.18, 95% CI: 0.08–0.28, p = 0.0003) across 10 randomised controlled trials (n = 522 participants). The effect was stronger in vegetarians and vegans, suggesting baseline creatine stores influence response magnitude. The mechanism is thought to involve creatine's role in maintaining ATP availability in the brain, particularly in the prefrontal cortex and hippocampus during demanding cognitive tasks.

In clinical populations, preliminary evidence is encouraging. Smith et al. (2025) conducted a pilot feasibility study of creatine monohydrate in mild cognitive impairment and early Alzheimer's disease (n = 24, 8-week duration) and found that supplementation was well-tolerated, brain creatine levels increased measurably on MR spectroscopy, and cognitive scores showed non-significant trends towards improvement. The sample was small and the study was not powered for efficacy, but it demonstrates that creatine crosses the blood–brain barrier and accumulates in neural tissue at clinically relevant doses.

I should note that some claims about creatine—such as its ability to treat depression or traumatic brain injury—remain preliminary. Sherpa et al. (2024) examined creatine as an add-on to cognitive-behavioural therapy in depression (n = 48, 8-week RCT) and found a larger reduction in depressive symptoms in the creatine group versus placebo (mean difference = −3.2 points on the PHQ-9, p < 0.05). However, the sample was small, the effect size was modest, and the clinical significance is unclear. I present this as evidence that warrants further investigation, not as established efficacy.

Dosage

Clinical trials typically employ one of two dosing protocols: a loading phase followed by maintenance, or maintenance dosing alone. The loading approach involves 20 g per day (divided into 4 × 5 g doses) for 5–7 days, followed by 3–5 g per day. The maintenance-only approach involves 3–5 g per day from day one, with muscle saturation occurring over 3–4 weeks. Both protocols result in similar muscle phosphocreatine concentrations after 28 days; loading simply accelerates the timeline. I chose 5000 mg (5 g) per serving because it sits at the upper end of the maintenance dose range, ensuring adequate daily intake without requiring a loading phase.

The UK and EU do not have formally established reference daily intake values for creatine monohydrate. The European Food Safety Authority (EFSA) and the UK Food Standards Agency (FSA) classify creatine as a food supplement ingredient with a history of safe use, but no specific RDA has been published. Clinical evidence supports 3–5 g daily as safe and effective; I positioned KōJō at 5 g to maximise response probability whilst remaining well within the evidence-based range. Individuals taking the full KōJō Daily Formula receive one serving per day, delivering the complete 5 g dose in a single intake.

Bioavailability and Forms

Creatine monohydrate exists in several commercial forms: standard micronised powder, monohydrate in capsule form, buffered creatine (creatine ethyl ester), and more recently, creatine hydrochloride. I selected micronised powder because the comparative evidence strongly favours it on three grounds: absorption, stability, and cost-effectiveness.

Kreider et al. (2022) reviewed bioavailability and efficacy data across creatine forms and concluded that standard creatine monohydrate and creatine monohydrate in capsule form show equivalent muscle phosphocreatine accumulation and performance outcomes when dosed at equivalent amounts. Micronisation improves dissolution rate and reduces gastrointestinal transit time, which may enhance consistency of absorption, but does not fundamentally alter the magnitude of effect. Buffered creatine and creatine ethyl ester have been marketed as superior alternatives, but head-to-head trials show no advantage over monohydrate when dosed at equivalent amounts. Creatine hydrochloride requires lower doses (1.5–3 g) to achieve similar effects, but the cost per gram is substantially higher, and the long-term safety profile is less established.

I chose micronised powder for practical and economic reasons: it dissolves readily in water or other beverages, requires no capsule manufacturing (reducing material waste), and costs approximately 40–50% less per gram than alternative forms. The evidence does not support paying a premium for alternative forms unless you have specific gastrointestinal sensitivity to standard monohydrate, which is rare.

Why I Formulated It This Way

I included 5000 mg of micronised creatine monohydrate in KōJō Daily Formula because it meets my core formulation principles: the evidence base is substantial and reproducible, the dose is evidence-based and safe, and the form is cost-effective without sacrificing bioavailability. Creatine is not a stimulant and does not produce acute subjective effects like caffeine or L-theanine; it is a substrate that works over days and weeks by incrementally increasing cellular energy availability. This makes it ideal for a daily formula designed for long-term use rather than acute performance.

The 5 g dose ensures that users who take one serving daily receive a full maintenance dose without needing to load or take multiple servings. I did not include a loading protocol in the formula because most users will take KōJō Daily Formula as an ongoing supplement, and the loading phase offers only a marginal time advantage (reaching muscle saturation in 5–7 days instead of 3–4 weeks). For individuals who want to load, the formula is compatible with a separate loading protocol, though I recommend consulting a healthcare professional before deviating from the standard serving size.

How KōJō Compares to Other UK Supplements

KōJO's creatine monohydrate dose matches the leading UK supplement brands—5 g of micronised powder per serving is the evidence-based standard. The key difference is that KōJō delivers this as part of a multi-nutrient daily formula rather than as a standalone ingredient. This means you receive creatine alongside other evidence-backed nutrients in a single serving, rather than needing to purchase and mix multiple products. If your primary goal is creatine supplementation alone, standalone creatine products from Myprotein, Optimum Nutrition, or Bulk Powders offer equivalent dosing at lower cost. If you want a multi-ingredient formula designed for daily nutritional support, KōJó integrates creatine with other actives in a single dose.

Safety and Considerations

Creatine monohydrate has an extensive safety record spanning over 25 years of clinical research. Poortmans et al. (2001) reviewed adverse effects of creatine supplementation and concluded that at doses up to 20 g per day for extended periods, creatine monohydrate does not cause renal, hepatic, or muscular harm in healthy individuals. More recent systematic reviews have reinforced this conclusion. The most commonly reported side-effect is mild gastrointestinal discomfort (bloating, nausea) in approximately 5–10% of users, typically during the loading phase. This is usually transient and resolves with dose reduction or switching to a micronised form, which I use in KōJó Daily Formula.

Consult a healthcare professional before starting creatine monohydrate if you are pregnant, breastfeeding, taking medication, or have an underlying condition—particularly kidney disease, liver disease, or diabetes. Although the evidence does not indicate that creatine harms renal function in healthy individuals, individuals with pre-existing kidney impairment may accumulate creatinine (a metabolite) more readily. KōJó Daily Formula provides 5000 mg of micronised creatine monohydrate per serving; do not exceed the recommended serving size without professional guidance. Creatine supplementation may increase body weight by 1–2 kg within the first 2 weeks due to increased intramuscular water retention—this is not fat gain and reverses upon cessation.

Frequently Asked Questions